PAIR-1: Prostate AI Research-1

• Research type

  Research Study

• Full title

  PAIR-1: Prostate AI Research-1

• IRAS ID

  278640

• Contact name

  Aarti Shah

• Contact email

  aarti.shah@hhft.nhs.uk

• Sponsor organisation

  Hampshire Hospitals NHS Foundation Trust

• Duration of Study in the UK

  5 years, 0 months, 1 days

• Research summary

  Prostate cancer is the most common cancer among men in the UK. MRI scans are now used to help reduce the need for biopsies (removing small amounts of tissue for lab testing) and improve the way cancers that require treatment are found. Specially developed computer software, known as Artificial Intelligence (AI) based software, can be used to examine scans and may give quicker and better results.
  
  Lucida Medical (previously known as Cambridge AI Health) has developed AI software to help find prostate cancer in MRI scans. The AI software could help specialists to be more accurate and assess more scans more quickly. Before this can happen, the AI software must be tested to confirm it works as it should. It has been developed (and will be CE marked) with information collected in 2011 from 80 patients using two similar scanners at one hospital in the Netherlands. This study will check the software works well in the UK with a broader range of information based on care given today. This is important because there can be differences in the images from different scanners, the way hospitals run the scans and differences between patients.

  The records of around 2000 patients who went through treatment at 6 NHS sites are needed to check the AI-based software. All scans will be anonymised so that the information analysed in the study cannot be used to identify any individual patients. As the study looks back at the care that has already been given, it will not affect anyone’s individual care. Part of the information will firstly be used to ensure that the software will work well across a range of equipment and scanning methods in different hospitals. The rest of the information will be used to test how well the software works to find prostate cancer.

• REC name

  N/A

• REC reference

  N/A